Diagnostics group cleared to sell in Australian market

Lyn Rees
Yourgene, the Manchester-based molecular diagnostics group, has confirmed that its chemotoxicity diagnostics assay – Elucigene DPYD – which tests to identify cancer patients at risk of lethal side effects from chemotherapy, has been approved for sale in Australia.Approval is from the Therapeutic Goods Administration (TGA), which is the regulatory body for therapeutic goods in Australia.It is a division of the Australian Department of Health established under the Therapeutic Goods Act 1989.In September 2019, Yourgene an... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...